Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK DDI Study of TGRX-326 with Itraconazole or Efavirenz
NCT06294561Phase 1Completed
- Sponsor
- Shenzhen TargetRx
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of deulorlatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shenzhen TargetRx. Primary endpoints: Plasma Time to Maximum Concentration at Day 20, Plasma Maximum Concentration at Day 20 and 5 more. Started Mar 2024; status: completed.
02
Drugs
deulorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06294561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06294561.